Navigation Links
How Candida albicans transforms from its normally benign form into life-threatening form
Date:10/4/2007

Researchers at the Agency for Science, Technology and Research's (A*STAR) Institute of Molecular and Cell Biology (IMCB) have discovered new molecular mechanisms that provide a more detailed understanding of how the normally benign Dr. Jekyll-like fungus known as Candida albicans transforms into a serious and often life-threatening Mr. Hyde-like form.

C. albicans can cause serious and potentially life-threatening infections in the mouth, blood and other tissues of people who are undergoing cancer chemotherapy or radiation treatments, or who have developed AIDS or other diseases that damage the immunity of the individual.

In two separate papers published last month in Developmental Cell and in August in the EMBO journal, the team of scientists led by Wang Yue, principal investigator at IMCB, have managed to reveal previously unknown mechanisms which are responsible for causing the infectious phase of C. albicans.

The fungus starts its 'attack' on a patient by changing its oval shape into a filamentous form, which has thin, threadlike appendages emerging from the cell body. Wang's team, who has been studying C. albicans for more than seven years, was responsible for identifying the master "controller" protein called Hgc1 in 20041.

This "controller" functions like a regulator and tells the fungus when to start the transformation from the harmless oval shape to the infectious filamentous form.

"One question remained, however - how does it activate the cellular machineries that determine the fungal cell shape?" said Wang.

Wang's team found the answer to this question in two proteins called Rga2 and Cdc11. They discovered that they each function like a switch on two different cellular machineries that normally determines cell shape. "The master regulator Hgc1 acts like the 'finger' that flips the switches to start the infection process," said Wang.

"Our findings have uncovered detailed molecular mechanisms which define how these two proteins interact with the master 'controller' to cause infections. This has opened new opportunities for us to investigate further into a new range of therapeutic targets for fungal infections," explained Wang.

In the same issue of Developmental Cell, the team's work was given an expert mention by a leading C. albicans researcher, Dr. Peter Sudbery, stating its importance in bringing awareness of the cellular processes that is necessary for C. albicans to transform to its infectious state.

In addition, the new knowledge of the detailed interaction of these proteins with other cellular machineries has also revealed critical information on how cells in general determine their shape, a fundamental question in biology as Rga2 and Cdc11 are also found in nearly all eukaryotic organisms.

Largely due to the AIDS pandemic in the last 25 years, the once nearly harmless and commensal fungus Candida albicans has become one of the most prevalent microbial pathogens in AIDS patients, causing life-threatening infections with high death rate, especially in infected children.


'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related medicine news :

1. Candidate vaccine to reduce hepatitis C viral load.
2. New Test Identifies Candidates For Cardiac Defibrillator
3. HIV-Positive Woman To Be Congress Candidate In Assam
4. Reservation For SC/ST Candidates Under 50% All India Quota
5. DBT And IAVI Forge Partnership To Develop “Next Generation” Vaccine Candidats
6. Republican Presidential Candidates Discuss Abortion, Stem Cells as Part of First Debate
7. DBT And IAVI Forge Partnership To Develop Next Generation Vaccine Candidates
8. Transformed Transforms Physician Centered Practice To Patient Centered One
9. Carriers With Alzheimers High Risk Gene Type Age Normally Until the Disease Strikes
10. Cannibalistic Signals Help Mammalian Embryos Develop Normally
11. Benign eye tumors being treated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: